Brovana Approval History

• FDA approved: Yes (First approved October 6th, 2006)
• Brand name: Brovana
• Generic name: arformoterol tartrate
• Company: Sepracor Inc.
• Treatment for: COPD

Brovana (arformoterol tartrate) is a long-acting beta2-agonist for inhalation via a nebulizer, used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

FDA Approval History for Brovana

Date	Article
Oct  6, 2006	Brovana Sepracor Inc. - Treatment for Chronic Obstructive Pulmonary Disease
Feb 13, 2006	Sepracor's Arformoterol NDA Filed by FDA; Drug Candidate for Chronic Obstructive Pulmonary Disease Moves Into Formal Review
Dec 13, 2005	Sepracor Announces Submission of Arformoterol NDA to FDA for Chronic Obstructive Pulmonary Disease

See also...

Brovana (arformoterol tartrate) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.